Research programme: cancer gene therapy - Transave

Drug Profile

Research programme: cancer gene therapy - Transave

Alternative Names: SLIT™ TR03; TR 03

Latest Information Update: 11 Sep 2005

Price : $50

At a glance

  • Originator Transave
  • Class Gene therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 11 Sep 2005 This programme is still in active development - (BIO-2005)
  • 18 Aug 2004 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top